Arabic Arabic English English French French German German

Live shingles vaccine shows safe, short-term efficacy for persons taking TNFis for inflammatory diseases

A randomized controlled trial found that the live shingles, or varicella-zoster, vaccine was safe and showed short-term efficacy for participants also taking tumor necrosis factor inhibitors (TNFis) for a broad range of inflammatory disorders. These finding suggest that a live virus vaccine in immunosuppressed patients receiving biologic therapies may be a reasonable option, especially for the zoster vaccine, if no alternative vaccine is available. The findings are published in Annals of Internal Medicine. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Anti-seizure medication improves cognitive function in some Alzheimer’s patients

Next Post

Two Europes: Low vaccine rates in east overwhelm ICUs

Related Posts